AI Summary
This study investigates the effectiveness of olanzapine-based prophylactic antiemetic therapy for managing nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan. The research aims to determine the impact of this regimen on delayed and persistent symptoms during the first cycle of treatment. The findings could provide insights into improving the quality of life for these patients undergoing T-DXd therapy.
Nausea and vomiting are common adverse events associated with trastuzumab deruxtecan (T-DXd). We evaluated the efficacy of an olanzapine-based triplet regimen for preventing nausea and vomiting in patients receiving first cycle T-DXd.